

In-line 1Q, backward integration to lead all the way

Divi's reported an in-line Q1 despite a beat on margins due to higher tax spend. Sales grew 13% YoY, 10% QoQ at Rs196bn. Healthy gross margins at 67% (backward integration coupled with better process technology reduces dependency) and better product mix (Generic and Custom Synthesis contributed 50% each with Custom Synthesis also recording Molnupiravir sales in Q1, we estimate Rs2bn) aided margins at 43.5% vs our expectation of 40.5%. Adjusting for forex loss of Rs190mn, PAT came in at Rs5.4bn exactly in line with our estimates. Divi's highlighted 6 key growth engines that would continue to drive 10-15% revenue growth in the medium term with sustained margins. Capex for the current growth drivers is already in the last stage and progressing well. Key point to note is that management remains confident on future of generic APIs and believes that end-to-end integration coupled with better process technology are its key success levers.

Key triggers: (1) Raw material dependency lowered significantly due to backward integration process, further scope to reduce China dependency (2) Earmarked capex of Rs3.7bn to generate 2x asset turn (Rs1.8bn started from FY18, Rs0.4bn for custom synthesis and Rs1.5-2bn for Kakinada and Krishnapatnam greenfield projects) (3) 6 growth engines: established generics (MS>70%), new generics (capacity increased), newer molecules like contrast media API, added 16 new generic APIs to lead next phase of growth, 2 big long term custom synthesis projects on fast track and to add new molecules in sartans (edge over NDMA issues for other players), (4) Molnupiravir API supplies.

Key Risks: Decline in tonnage requirements of NCEs in custom synthesis segment could bring down the addressable opportunity size.

Outlook and Valuation: 1Q was yet again a strong quarter driven by volume growth across the product portfolio. After 4 flat quarters on top-line front (QoQ), 10% QoQ growth in Q1 is a respite. With significant capacity addition, we believe Divi's is well positioned to gain share from competitors in existing products, particularly, given the ongoing shift from China. Divi's asset base has doubled over last 3 years. FY21 gross asset turn is at 1.6x vs FY19 peak of 1.9x. After funding of Rs50bn of cumulative capex over last 10 years (>50% in last 3 years), Divi's generated Rs42bn cumulative free cash in 10 years, ~25% in FY21 alone.

Q1FY22 Result (Rs Mn)

Particulars	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)
Revenue	19,606	17,305	13.3	17,882	9.6
Total Expense	11,086	10,304	7.6	10,719	3.4
EBITDA	8,521	7,001	21.7	7,163	19.0
Depreciation	733	562	30.4	701	4.5
EBIT	7,788	6,439	21.0	6,462	20.5
Other Income	360	173	107.6	235	52.9
Interest	3	2	21.7	2	33.3
EBT	8,145	6,610	23.2	6,695	21.7
Tax	2,574	1,689	52.4	1,675	53.7
RPAT	5,571	4,921	13.2	5,020	11.0
APAT	5,441	4,885	11.4	4,991	9.0
			(bps)		(bps)
Gross Margin (%)	67.2	63.0	422	67.5	(24)
EBITDA Margin (%)	43.5	40.5	300	40.1	340
NPM (%)	28.4	28.4	(2)	28.1	34
Tax Rate (%)	31.6	25.6	604	25.0	658
EBIT Margin (%)	39.7	37.2	251	36.1	359

CMP	Rs 4,916
Target / Upside	Rs 5,400 / 10%
NIFTY	16,238

Scrip Details

Equity / FV	Rs 531mn / Rs 2
Market Cap	Rs 1,305bn
	USD 17.5bn
52-week High/Low	Rs 5,045/ 2,722
Avg. Volume (no)	540,296
Bloom Code	DIVI IN

Price Performance	1M	3M	12M
Absolute (%)	9	22	77
Rel to NIFTY (%)	6	12	34

Shareholding Pattern

	Dec'20	Mar'21	Jun'21
Promoters	52.0	52.0	52.0
MF/Banks/FIs	25.6	24.5	21.8
FII's	20.4	19.9	20.6
Public / Others	2.1	3.7	5.7

Valuation (x)

	FY21E	FY22E	FY23E
P/E	65.8	54.9	46.0
EV/EBITDA	44.9	37.3	30.9
ROE (%)	23.9	24.2	24.9
RoACE (%)	22.9	23.3	24.0

Estimates (Rs mn)

	FY21E	FY22E	FY23E
Revenue	69,694	85,035	100,162
EBITDA	28,599	34,175	40,674
PAT	19,843	23,777	28,371
EPS (Rs.)	74.8	89.6	106.9

VP - Research: Sapna Jhawar

Tel: +9122 40969724

E-mail: sapnaj@dolatcapital.com

Associate: Zain Gulam Hussain

Tel: +9122 40969725

E-mail: zain@dolatcapital.com

Exhibit 1: Revenue breck-up

(Rs mn)	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)	FY20	FY21	YoY (%)
Generic API	9,803	8,934	9.7	10,729	(8.6)	47,633	40,367	18.0
Custom Synthesis	8,423	7,104	18.6	5,595	50.6	28,058	23,382	20.0
Nutraceuticals	1380.0	1267.0	8.9	1558.0	(11.4)	7015.1	5945.0	18.0
Total Sales	19,606	17,305	13.3	17,882	9.6	82,707	69,694	18.7

Source: DART, Company

With capacity related bottlenecks now addressed, Divi's has also identified 6 engines to drive 10-15% growth in the medium term. We expect strong market share gains and introduction of new APIs to drive robust 20% sales/PAT CAGR each over FY21-23E. We remain constructive on EBITDA margin sustenance at ~40% over next 2 years despite incremental costs from newly commissioned capacities. Divi's is trading at 46x FY23E, its growth justifying the premium valuations vs peers. Our SOTP based target price of Rs5,400 values it at 50x.

Key Con-call takeaways

- 1) **6 growth engines:** Divi's highlighted 6 key engines that would drive 10-15% growth over the next few years. Capex for these growth engines are already in place.
 - a. **Established generics:** Products where Divi's has >70% market share and will continue to grow ~10%. Divi's enjoy 70-90% market share in products like Naprozen, Gabapentin, Dextromethorphan
 - b. **Increased capacity utilization of existing generics:** Products where market share is ~20-30% target is to achieve 60-70% MS via higher capacity utilization
 - c. **Sartan APIs:** Divi's is end-to-end integrated for sartans which gives it a competitive edge over other players in terms of cost as well as NDMA impurities. Company plans to enter into newer sartans as well.
 - d. **Contrast Media:** Divi's aims to become the largest player in contrast media APIs. It has signed new contracts with innovators and expects good growth over next 2 years.
 - e. **Custom Synthesis:** Divi's signed 2 new long term contracts with innovators to be completed on a fast track basis.
 - f. **New generics:** Company has identified 16 new molecules (large volume but niche molecules) whose patents are set to expire over FY22-26.
- 2) **Capex Update:** Its planned capex of Rs37bn is progressing well with
 - a. Majority debottlenecking capex of Rs4bn completed and ~80% of capacity is utilized currently. This has reduced dependency on KSMs from China
 - b. Since 2018, Divi's has undertaken capex of Rs25bn of which Rs18bn is operational and revenue generating, another Rs5bn capex is in validation stage
 - c. Capitalized assets of Rs2.7bn in Q1
 - d. Supreme Court has given final approval in favour of Divi's for its Kakinada plot. Work should resume by end of Q2, so far company has invested Rs1.8bn at Kakinada. Will re-assess its filings from here and invest ~Rs1-2bn for Kakinada and Krishnapatnam port greenfield projects.

- 3) **Molnupiravir:** Divi's is one of the largest authorized supplier for Merck in the US, EU and other regulated markets. Divi's is also allowed to supply Molnupiravir API to MSD's licensed partners for India and 103 other LMICs. Our analysis suggests Divi's could achieve Rs10bn of Molnupiravir sales in FY22E (Q1 estimated sales is Rs2bn). One stream has already started producing Molnupiravir and the second stream validation is completed and is ready for commercial supplies. Molnupiravir API from these two streams would be exported directly to Merck. In addition, Divi's has created an additional stream at Unit 1 to supply the API to Merck's LMIC partners (Sun Pharma, Dr. Reddy's, Cipla, Hetero Labs and Emcure).
- 4) **Logistics challenge:** Management admitted that it was facing some hiccups in supply chain but end-to-end integration aided in smoothening the process. Majority issues faced in areas of raw materials, solvents and export batches. **In order to overcome these challenges, it is now arranging for raw materials from EU and US by paying ~10-15% higher cost. With strong balance sheet and no working capital issues it can easily afford higher input costs without impacting growth.**
- 5) **Revenue mix:** In 1Q, API:CS ratio was split as 50:50 with nutraceuticals generating revenue of Rs1.38bn. Company guided that an ideal mix should likely be at 50:50 from Generics and CS, however, this might take few years. Currently top 5 products contribute around 47% to revenues of which top 2 products, Naproxen and Dextromethorphan account for 25% of sales. As far as geography wise mix is concerned, Divi's generated 71% of sales from US and EU in FY21. Total exports contribution is 89% in Q1FY22.
- 6) **Generic API:** As large part of the capacity expansion is complete; management remains optimistic of strong growth sustenance in API in FY22E even for its top 5 molecules. It has commenced supplies from blocks which are FDA approved post the expansion. Further, management has identified 16 new molecules for future growth (some of them are yet to go off-patent in 2025), addressable market opportunity of US\$12bn. Validations for 3 APIs is completed and company is preparing for DMF filings. 3 are under validation, 7 have samples and 3 are under in early stage of development. Currently it has around 30 products in the Generic API portfolio and is amongst the top 2 producers in 18 of the 30 APIs. **Despite being older products (>25 years), Divi's continue to cater to 60-90% of several APIs across the world and hence able to command premium vs competitors. Management believes that opportunity on few APIs is still 2-3x from here. Generic API market is growing at 5-7% p.a.**
- 7) **Custom Synthesis:** Divi's highlighted that it has not witnessed any slowdown in clinical activities during COVID. In-fact the enquiries for CS projects have been on the higher side as innovators across the globe are working on COVID products. Its Rs4bn capex is progressing well and production has started at one of the blocks. As Divi's offers largely phase 2 and 3 and launch commercial supplies, we expect the current order-book could add a hefty chunk of growth leading the way for Divi's. Management expects the all facilities to be up and running by 2HFY22E.
- 8) **Nutraceutical:** Nutraceuticals is now 10% of total sales with ~95% of its sales coming from US and EU. Company is seeing opportunities in this segment and has doubled its production capacity given the strong demand visibility. Carotenoid global market size is US\$1.5bn and is expected to grow at CAGR of 4% over FY19-26E. **Divi's is backward integrated for the production of API and finished forms of carotenoid, with a full-fledged R&D, application testing, and support facility under one roof at the Unit II facility. Its competitors produce APIs and finished forms at different locations, hence, they have a higher cost profile.**

Profit and Loss Account

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Revenue	53,944	69,694	85,035	100,162
Total Expense	35,723	41,095	50,860	59,488
COGS	21,085	23,241	28,972	33,449
Employees Cost	6,211	8,258	10,117	11,906
Other expenses	8,427	9,596	11,771	14,133
EBIDTA	18,222	28,599	34,175	40,674
Depreciation	1,862	2,556	3,077	3,500
EBIT	16,359	26,044	31,099	37,174
Interest	61	9	7	5
Other Income	1,896	626	683	746
Exc. / E.O. items	0	0	0	0
EBT	18,195	26,660	31,774	37,914
Tax	4,429	6,818	7,998	9,543
RPAT	13,765	19,843	23,777	28,371
Minority Interest	0	0	0	0
Profit/Loss share of associates	0	0	0	0
APAT	14,387	19,843	23,777	28,371

Balance Sheet

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
Sources of Funds				
Equity Capital	531	531	531	531
Minority Interest	0	0	0	0
Reserves & Surplus	72,568	92,415	103,234	123,372
Net Worth	73,099	92,946	103,765	123,903
Total Debt	336	4	4	4
Net Deferred Tax Liability	3,014	3,695	4,097	4,529
Total Capital Employed	76,450	96,645	107,865	128,436

Applications of Funds

Net Block	27,768	36,996	41,919	44,419
CWIP	9,248	7,149	3,596	1,819
Investments	1,190	1,295	1,295	1,295
Current Assets, Loans & Advances	47,152	62,300	72,812	93,990
Inventories	18,639	21,452	22,166	24,259
Receivables	14,134	16,765	18,479	20,387
Cash and Bank Balances	1,226	21,560	29,177	46,098
Loans and Advances	354	553	680	800
Other Current Assets	3,086	1,969	2,310	2,446
Less: Current Liabilities & Provisions	8,907	11,096	11,758	13,089
Payables	5,907	7,632	8,062	9,283
Other Current Liabilities	3,000	3,464	3,696	3,806
<i>sub total</i>				
Net Current Assets	38,244	51,204	61,054	80,902
Total Assets	76,450	96,645	107,865	128,436

E – Estimates

Important Ratios

Particulars	FY20A	FY21E	FY22E	FY23E
(A) Margins (%)				
Gross Profit Margin	60.9	66.7	65.9	66.6
EBIDTA Margin	33.8	41.0	40.2	40.6
EBIT Margin	30.3	37.4	36.6	37.1
Tax rate	24.3	25.6	25.2	25.2
Net Profit Margin	25.5	28.5	28.0	28.3
(B) As Percentage of Net Sales (%)				
COGS	39.1	33.3	34.1	33.4
Employee	11.5	11.8	11.9	11.9
Other	15.6	13.8	13.8	14.1
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	268.2	2993.5	4442.7	7080.7
Inventory days	126	112	95	88
Debtors days	96	88	79	74
Average Cost of Debt	8.8	5.1	200.0	150.0
Payable days	40	40	35	34
Working Capital days	259	268	262	295
FA T/O	1.9	1.9	2.0	2.3
(D) Measures of Investment				
AEPS (Rs)	54.2	74.8	89.6	106.9
CEPS (Rs)	61.2	84.4	101.2	120.1
DPS (Rs)	38.6	20.0	22.0	24.2
Dividend Payout (%)	71.2	26.8	24.6	22.6
BVPS (Rs)	275.4	350.1	390.9	466.8
RoANW (%)	19.3	23.9	24.2	24.9
RoACE (%)	18.5	22.9	23.3	24.0
RoAIC (%)	22.2	34.7	40.4	46.2
(E) Valuation Ratios				
CMP (Rs)	4916	4916	4916	4916
P/E	90.7	65.8	54.9	46.0
Mcap (Rs Mn)	1,304,952	1,304,952	1,304,952	1,304,952
MCap/ Sales	24.2	18.7	15.3	13.0
EV	1,294,349	1,283,395	1,275,778	1,258,858
EV/Sales	24.0	18.4	15.0	12.6
EV/EBITDA	71.0	44.9	37.3	30.9
P/BV	17.9	14.0	12.6	10.5
Dividend Yield (%)	0.8	0.4	0.4	0.5
(F) Growth Rate (%)				
Revenue	9.1	29.2	22.0	17.8
EBITDA	(2.7)	57.0	19.5	19.0
EBIT	(3.9)	59.2	19.4	19.5
PBT	(1.9)	46.5	19.2	19.3
APAT	6.4	37.9	19.8	19.3
EPS	6.4	37.9	19.8	19.3

Cash Flow

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
CFO	13,256	20,839	25,029	29,382
CFI	(598)	1,733	(4,447)	(4,223)
CF	(12,584)	(2,238)	(12,965)	(8,238)
FCFF	12,657	22,572	20,582	25,159
Opening Cash	1,153	1,226	21,560	29,177
Closing Cash	1,226	21,560	29,177	46,098


E – Estimates

DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Sep-20	Accumulate	3,505	3,211
Nov-20	Accumulate	3,515	3,237
Feb-21	Accumulate	3,554	3,822
May-21	Accumulate	4,386	4,120

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747
--------------------	--------------------------	--------------------------------	------------------------

Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745
--------------------------	-------------------------	------------------------------	------------------------

CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772
Anjana Jhaveri	VP - FII Sales	anjanaj@dolatcapital.com	+9122 4096 9758
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Dinesh Mehta	Co - Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

Dolat Capital Market Private Limited.

Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013

Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: "This Report is considered independent third-party research and was prepared by Dolat Capital Market Private Limited, with headquarters in India. The distribution of this Research is provided pursuant to the exemption under Rule 15a-6(a) (2) and is only intended for an audience of Major U.S. Institutional Investors (MUSIIs) as defined by Rule 15a-6(b)(4). This research is not a product of StoneX Financial Inc. Dolat Capital Market Private Limited has sole control over the contents of this research report. StoneX Financial Inc. does not exercise any control over the contents of, or the views expressed in, any research reports prepared by Dolat Capital Market Private Limited and under Rule 15a-6(a) (3), any U.S. recipient of this research report wishing to affect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through StoneX Financial Inc. Please contact Paul Karrlsson-Willis at +1 (407) 741-5310 or email Paul.Karrlsson-Willis@stonex.com and/or Igor Chernomorskiy at +1 (212)379-5463 or email Igor.Chernomorskiy@stonex.com. Under no circumstances should any U.S. recipient of this research report effect any transaction to buy or sell securities or related financial instruments through the Dolat Capital Market Private Limited."



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000000685

Registered office: Unit no PO6-02A - PO6-02D, Tower A, WTC, Block 51, Zone-5, Road 5E, Gift City, Gandhinagar, Gujarat – 382355

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com
